188 completed, 41 unknown, 35 terminated, 22 withdrawn. 294 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 294 | Completed 188, Unknown 41, Terminated 35, Withdrawn 22, Not yet recruiting 3, Recruiting 3, Active not recruiting 2 |
Follow Hepatitis C: new trials by email Literature Review of Hepatitis C trials Research Report on Hepatitis C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, INSTI HIV - 1/2 Antibody, bioLytical Laboratories iStatis Hepatitis B Surface Antigen Test - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-11-09 |
| AI-Powered Hepatitis C Single-Encounter Test-and-Treat Epclusa (sofosbuvir and velpatasvir) - HEPATITIS C (HCV) | Phase 4 | Not yet recruiting | Patrick Grace | 35 | 2026-12-01 | 2026-08-28 |
| Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy ACCESS+ strategy Epclusa 400/100 Oral Tablet, ACCESS+ Strategy Vosevi 400/100/100 Oral Tablet, Standard Strategy Vosevi 400/100/100 Oral Tablet - Hepatitis C Virus Infection | Phase 4 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 576 | 2025-09-01 | 2025-08-01 |
| Implementing Low-Barrier HCV Treatment in a Jail Setting Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker - HEPATITIS C (HCV), Incarceration | Phase 4 | Recruiting | Lifespan | 40 | 2025-06-11 | 2026-02-27 |
| UHN Inpatient Hepatitis C & B Screening Quality Improvement - Hepatitis C, Hepatitis B | Phase 4 | Unknown | Jordan Feld | 2920 | 2024-02-01 | 2024-02-08 |
| HCV Test and Treat Utilizing Simplified HCV Patient Education Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir - Hepatitis C | Phase 4 | Terminated | Weill Medical College of Cornell University | 8 | 2022-11-11 | 2025-02-27 |
| Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir - Hepatitis C, Cirrhosis | Phase 4 | Unknown | Peking University People's Hospital | 100 | 2022-09-01 | 2022-07-21 |
| Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30% Xpert HCV Viral load finger stick point of care test (Cepheid), Epclusa 400Mg-100Mg Tablet, Standard of care - Hepatitis C | Phase 4 | Completed | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 606 | 2022-07-25 | 2023-11-13 |
| Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil) Specialist - Epclusa 400Mg-100Mg Tablet, Non- specialist - Epclusa 400Mg-100Mg Tablet, HCV Self-Testing kit (Ora-Quick HCV ST or Wond-Foo HCV ST) - Hepatitis C | Phase 4 | Recruiting | Oswaldo Cruz Foundation | 30000 | 2022-07-04 | 2026-08-17 |
| HCV Treatment Initiation During Acute Psychiatric Admission HCV care provided by hospitalist during acute psychiatric admission - Hepatitis C | Phase 4 | Unknown | University Health Network, Toronto | 54 | 2022-04-19 | 2022-05-05 |
| Pharmacist-led Hepatitis C Management Pharmacist-Led care, Standard of Care (Hepatology) - Hepatitis C Virus Infection | Phase 4 | Unknown | University Health Network, Toronto | 108 | 2022-04-13 | 2022-04-27 |
| Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet - Hepatitis C, Chronic, Pregnancy; Infection | Phase 4 | Active not recruiting | Catherine Anne Chappell | 100 | 2022-04-04 | 2026-10-19 |
| Same-visit Hepatitis C Testing and Treatment (The QuickStart Study) OraQuick HCV Antibody test (OraSure Technologies, Inc), Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid), Sofosbuvir/Velpatasvir (Gilead) - Hepatitis C | Phase 4 | Unknown | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 1800 | 2022-03-09 | 2023-11-13 |
| Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) Glecaprevir/pibrentasvir - HCV Infection | Phase 4 | Withdrawn | University of Maryland, Baltimore | 2021-10-01 | 2021-05-06 | |
| The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China Tenofovir Alafenamide 25 MG, Sofosbuvir / Velpatasvir - Chronic Hepatitis C, Chronic Hepatitis B | Phase 4 | Unknown | Peking University First Hospital | 120 | 2021-08-01 | 2021-08-09 |
| QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir Glecaprevir and Pibrentasvir - Kidney Failure, Hepatitis C | Phase 4 | Terminated | Massachusetts General Hospital | 2 | 2021-05-01 | 2024-12-03 |
| Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin, Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] - Chronic Hepatitis C | Phase 4 | Completed | Helwan University | 281 | 2020-11-21 | 2022-09-02 |
| Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors Glecaprevir/pibrentasvir - End Stage Renal Disease, Hepatitis C | Phase 4 | Completed | Johns Hopkins University | 10 | 2020-11-20 | 2024-01-10 |
| Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] - End Stage Renal Disease, Chronic Hepatitis c | Phase 4 | Withdrawn | Massachusetts General Hospital | 2020-11-13 | 2022-03-08 | |
| HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial Velpatasvir/Sofosbuvir - Hepatocellular Carcinoma, Hepatitis C | Phase 4 | Completed | Alexandria University | 84 | 2020-10-05 | 2023-04-04 |
Showing 20 of 294. Sign in to see all of them.
Hepatitis C, Chronic (144) · HIV Infections (18) · Acquired Immunodeficiency Syndrome (14) · Fibrosis (9) · Insulin Resistance (8) · Kidney Failure, Chronic (8) · Liver Diseases (7) · Renal Insufficiency (7) · Hepatitis (6) · Carcinoma, Hepatocellular (5) · Coinfection (5) · Liver Cirrhosis (5) · Opioid-Related Disorders (5) · Renal Insufficiency, Chronic (5)
Blood-Borne Infections (294) · Communicable Diseases (293) · Digestive System Diseases (293) · Flaviviridae Infections (293) · Hepatitis, Viral, Human (293) · Infections (293) · RNA Virus Infections (293) · Virus Diseases (293) · Hepatitis (288) · Liver Diseases (287) · Pathological Conditions, Signs and Symptoms (168) · Pathologic Processes (166) · Disease Attributes (156) · Chronic Disease (152) · Hepatitis, Chronic (141)
Ribavirin (135) · peginterferon alfa-2a (83) · Sofosbuvir (39) · peginterferon alfa-2b (27) · sofosbuvir-velpatasvir drug combination (26) · elbasvir-grazoprevir drug combination (20) · ledipasvir, sofosbuvir drug combination (16) · glecaprevir and pibrentasvir (12) · velpatasvir (12) · elbasvir (10) · grazoprevir (9) · ledipasvir (9) · daclatasvir (8) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (7) · Simeprevir (6)
Hoffmann-La Roche (28) · Merck Sharp & Dohme LLC (11) · National Taiwan University Hospital (11) · Kirby Institute (10) · Massachusetts General Hospital (10) · Kaohsiung Medical University Chung-Ho Memorial Hospital (7) · University of California, San Francisco (5) · University of Maryland, Baltimore (5) · Brooke Army Medical Center (4) · Johns Hopkins University (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4) · Duke University (3) · Instituto de Investigación Marqués de Valdecilla (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Tehran University of Medical Sciences (3)
United States (110) · Taiwan (22) · Spain (19) · Canada (18) · Australia (15) · Egypt (14) · Germany (13) · Brazil (12) · France (9) · Italy (9) · South Korea (9) · Sweden (8) · United Kingdom (7) · Iran (6) · Puerto Rico (6)
Chen-Hua Liu, MD (7) · Ming-Lung Yu, MD, PhD (5) · Raymond T Chung, MD (5) · Jia-Horng Kao, MD, PhD (4) · Shih-Jer Hsu, MD (4) · Cheng-Chao Liang, MD (3) · Ding-Shinn Chen, MD (3) · Jee-Fu Huang, MD (3) · Raymond Chung, MD (3) · Stephen A Harrison, MD (3) · Bita Behnava, M.D. (2) · Bonaventura Clotet, MD, PhD (2)
PMID 26867206, PMID 30552056, PMID 37096802, PMID 11984144, PMID 12375147, PMID 15191208, PMID 16183464, PMID 17302380, PMID 17484872, PMID 17625124, PMID 17875007, PMID 17943989, PMID 18081737, PMID 18508296, PMID 18684176, PMID 18834319, PMID 19144941, PMID 19628656, PMID 20102281, PMID 20163377, PMID 20377423, PMID 20425880, PMID 20816836, PMID 21064034, PMID 21145855, PMID 21205057, PMID 21281434, PMID 21282185, PMID 21439960, PMID 21506241, PMID 21714878, PMID 21784046, PMID 21876446, PMID 22235243, PMID 22592094, PMID 23428875, PMID 23442834, PMID 23593611, PMID 23616960, PMID 23795661, PMID 23884067, PMID 23884071, PMID 23884073, PMID 24067879, PMID 24073301, PMID 24209977, PMID 24297189, PMID 24360571, PMID 24720702, PMID 24747867
2005 (4), 2004 (2), 2009 (2), 2015 (1), 2016 (1), K23DK082621 (1), R01DA013806 (1), R01DA016764 (1), R01DA033777 (1), R01DA047952 (1), R21DA016066 (1), R34DA061732 (1), U01AI115714 (1), U01AI195193 (1), U19AI111825 (1)